The National Institute for Health and Care Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Percutaneous thrombectomy for intermediate-risk or high ...

The National Institute for Health and Care Excellence (NICE) is producing guidance on ex-situ machine perfusion for deceased donor liver transplants. The draft scope has been developed by the NICE ...

In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over ...

The appraisal committee has prepared final draft guidance (FDG) on ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] and submitted it to NICE.

Information for the public Ruxolitinib cream (Opzelura) is not normally available on the NHS for treating non-segmental vitiligo (development of pale white patches) affecting the face in people 12 ...

Evidence-based recommendations on ruxolitinib cream (Opzelura) for treating non-segmental vitiligo in people 12 years and over ...

Ruxolitinib cream (Opzelura, Incyte) is indicated for 'the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age'.